Use of Tyrosine-Kinase Inhibitors in Medullary Thyroid Carcinoma: An Institutional Experience


Introduction: Medullary thyroid cancer (MTC) comprises 4% of thyroid tumors. 7-23% of patients (pts) have metastases at diagnosis. In some cases metastatic disease follows an indolent course, and in others it progresses rapidly, requiring systemic treatment. Tyrosine-kinase inhibitors (TKI) have demonstrated a median progression-free survival (PFS) of 11 months.

Aim(s): To analyze the clinicopathological and molecular features of patients receiving TKI treatment, thus assessing toxicity and efficacy in our practice.

Materials and methods: Observational study. Period: January 2008 - May 2016. Statistical analysis: IBM SPSS Statistics 22.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Luca R

Authors: Luca R, O'Connor J, Falco A, Do Pico F, Tsou F,

Keywords: TNE, TKI,

To read the full abstract, please log into your ENETS Member account.